Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The … Read more
Market Cap & Net Worth: Intra-Cellular Therapies Inc (ITCI)
Intra-Cellular Therapies Inc (NASDAQ:ITCI) has a market capitalization of $14.05 Billion ($14.05 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1319 globally and #1004 in its home market, demonstrating a 0.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intra-Cellular Therapies Inc's stock price $131.87 by its total outstanding shares 106522000 (106.52 Million).
Intra-Cellular Therapies Inc Market Cap History: 2015 to 2025
Intra-Cellular Therapies Inc's market capitalization history from 2015 to 2025. Data shows growth from $5.73 Billion to $14.05 Billion (12.33% CAGR).
Index Memberships
Intra-Cellular Therapies Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.62% | #28 of 976 |
Weight: Intra-Cellular Therapies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Intra-Cellular Therapies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intra-Cellular Therapies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.07x
Intra-Cellular Therapies Inc's market cap is 13.07 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.73 Billion | $91.36K | -$104.79 Million | 62714.18x | N/A |
| 2016 | $1.61 Billion | $330.70K | -$116.43 Million | 4860.62x | N/A |
| 2017 | $1.54 Billion | $245.84K | -$97.77 Million | 6274.23x | N/A |
| 2019 | $3.65 Billion | $60.61K | -$147.72 Million | 60296.80x | N/A |
| 2020 | $3.39 Billion | $22.53 Million | -$227.01 Million | 150.35x | N/A |
| 2021 | $5.58 Billion | $81.71 Million | -$284.13 Million | 68.24x | N/A |
| 2022 | $5.64 Billion | $249.13 Million | -$256.26 Million | 22.63x | N/A |
| 2023 | $7.63 Billion | $464.37 Million | -$139.67 Million | 16.43x | N/A |
| 2024 | $8.90 Billion | $680.85 Million | -$74.68 Million | 13.07x | N/A |
Competitor Companies of ITCI by Market Capitalization
Companies near Intra-Cellular Therapies Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Intra-Cellular Therapies Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Intra-Cellular Therapies Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Intra-Cellular Therapies Inc's market cap moved from $5.73 Billion to $ 14.05 Billion, with a yearly change of 12.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $14.05 Billion | +57.89% |
| 2024 | $8.90 Billion | +16.62% |
| 2023 | $7.63 Billion | +35.34% |
| 2022 | $5.64 Billion | +1.11% |
| 2021 | $5.58 Billion | +64.59% |
| 2020 | $3.39 Billion | -7.32% |
| 2019 | $3.65 Billion | +201.23% |
| 2018 | $1.21 Billion | -21.34% |
| 2017 | $1.54 Billion | -4.04% |
| 2016 | $1.61 Billion | -71.95% |
| 2015 | $5.73 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Intra-Cellular Therapies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.05 Billion USD |
| MoneyControl | $14.05 Billion USD |
| MarketWatch | $14.05 Billion USD |
| marketcap.company | $14.05 Billion USD |
| Reuters | $14.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.